A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
NCT ID: NCT00377234
Last Updated: 2016-08-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
356 participants
INTERVENTIONAL
2006-05-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
NCT02604836
A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis
NCT01128257
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
NCT00081653
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
NCT02598440
A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
NCT00545051
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
ibandronate [Bonviva/Boniva]
150mg po monthly for 3 months
2
Risedronate
35mg po weekly for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risedronate
35mg po weekly for 12 weeks
ibandronate [Bonviva/Boniva]
150mg po monthly for 3 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients who are bisphosphonate-naive, or who have previously received oral daily or i.v. bisphosphonate therapy (fulfilling certain criteria detailed in the protocol).
Exclusion Criteria
* inability to stand or sit upright for at least 60 minutes;
* disease/disorder/treatment with drugs known to influence bone metabolism.
55 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Mesa, Arizona, United States
Scottsdale, Arizona, United States
Jonesboro, Arkansas, United States
Anaheim, California, United States
San Diego, California, United States
Waterbury, Connecticut, United States
Boynton Beach, Florida, United States
Jupiter, Florida, United States
Largo, Florida, United States
Leesburg, Florida, United States
Merritt Island, Florida, United States
Ocala, Florida, United States
Pembroke Pines, Florida, United States
Spring Hill, Florida, United States
St. Petersburg, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Douglasville, Georgia, United States
Gainesville, Georgia, United States
Marietta, Georgia, United States
Madisonville, Kentucky, United States
Bethesda, Maryland, United States
Missoula, Montana, United States
Omaha, Nebraska, United States
Morehead City, North Carolina, United States
New Bern, North Carolina, United States
Jamestown, North Dakota, United States
Cincinnati, Ohio, United States
Cincinnati, Ohio, United States
Mogadore, Ohio, United States
Tulsa, Oklahoma, United States
Duncansville, Pennsylvania, United States
Erie, Pennsylvania, United States
Feasterville, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Anderson, South Carolina, United States
Memphis, Tennessee, United States
Selmer, Tennessee, United States
Bedford, Texas, United States
Bryan, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Temple, Texas, United States
Richmond, Virginia, United States
Richmond, Virginia, United States
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MA19547
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.